Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1CNS 1

Conditions

Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Neoplasm Metastasis 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Melanoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Neuroendocrine 1Anophthalmia with pulmonary hypoplasia 1

Interventions

Nivolumab 6atezolizumab 5Cisplatin 5Ipilimumab 4Carboplatin 4Etoposide 3pembrolizumab 2gallium Ga 68 dotatate 2dostarlimab 2Temozolomide 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Magnetic Resonance Imaging 2Irinotecan 2Immunoglobulin G 2IFL protocol 2Fluorouracil 2Disulfides 2zimberelimab 1tivozanib 1repotrectinib 1niraparib 1lutetium Lu 177 dotatate 1lenvatinib 1iadademstat 1durvalumab 1cabozantinib 1budigalimab 1belinostat 1Topotecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × budigalimab × 1 year × Clear all
NCT05599984 2026-05-07

Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors

AbbVie

Phase 1 Active not recruiting
288 enrolled
CNSEndocrineThoracic

Neoplasms, Central Nervous System Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡